Implantable cardiac pacing systems are a safe and effective treatment for symptomatic
irreversible bradycardia. Under the proper indications, cardiac pacing might bring
significant clinical benefit. Evidences from literature state that the action of the
artificial pacing system, mainly when the ventricular lead is located at the apex of
the right ventricle, produces negative effects to cardiac structure (remodeling,
dilatation) and function (dissinchrony). Patients with previously compromised left
ventricular function would benefit the least with conventional right ventricle apical
pacing, and are exposed to the risk of developing higher incidence of morbidity and
mortality for heart failure. However, after almost 6 decades of cardiac pacing, just
a reduced portion of patients in general would develop these alterations. In this
context, there are not completely clear some issues related to cardiac pacing and the
development of this cardiomyopathy. Causality relationships among QRS widening with a
left bundle branch block morphology, contractility alterations within the left
ventricle, and certain substrates or clinical (previous systolic dysfunction,
structural heart disease, time from implant) or electrical conditions (QRS duration,
percentage of ventricular stimulation) are still subjecte of debate. This review
analyses contemporary data regarding this new entity, and discusses alternatives of
how to use cardiac pacing in this context, emphasizing cardiac resynchronization
therapy.